CAR-Cell Reality Check
Audit status: evidence, registry, and safety/operations layers refreshed 16 Sep 2026. Adjacent non-CAR T-cell engagers remain opt-in and excluded by default.
Current safety signal · verified 16 Sep 2026
Novartis reported temporarily pausing screening, randomization, and dosing in eight autoimmune/neuroscience rap-cel studies after three fatal IEC-HS events. Bristol Myers Squibb separately reported a voluntary enrollment pause across its zola-cel autoimmune program while reviewing transient, reversible inflammatory events. No public restart or resolution was identified in the checked sources through 16 Sep 2026. Sponsor actions are displayed separately from registry recruitment status, which may lag. The exposed denominator and trial/disease allocation of the reported events are not public, so no incidence is calculated.
New operational changes: Brazil Anvisa suspended three named rap-cel protocols effective 15 Sep; this is a jurisdiction-specific regulatory action and does not add another safety-event count. FDA granted obe-cel RMAT designation for SLE/lupus nephritis on 9 Sep; RMAT is an accelerated-development pathway, not product approval or proof of efficacy.
Published context, not pooled: a 2026 systematic review of 38 studies/115 patients (search through Dec 2025) reported CRS in 70.4%, ICANS in 4.3%, and infections in nearly half. Because it is a secondary, overlapping synthesis that predates these program pauses, it is shown only as context and never added to dashboard numerators. PMID 42709343.